Nanotheranostics最新文献

{"title":"Drug Encapsulated Lipid-Polymeric Nanohybrid as a Chemo-therapeutic Platform of Cancer.","authors":"Rahul Kumar,&nbsp;Vinish Ranjan Srivastava,&nbsp;Supratim Mahapatra,&nbsp;Daphika S Dkhar,&nbsp;Rohini Kumari,&nbsp;Kumari Prerna,&nbsp;Vikash Kumar Dubey,&nbsp;Pranjal Chandra","doi":"10.7150/ntno.81173","DOIUrl":"https://doi.org/10.7150/ntno.81173","url":null,"abstract":"<p><p>The focus of this research is to design a bioengineered drug delivery vehicle that is efficient in anti-cancer drug delivery in a controlled manner. The experimental work focuses on constructing a methotrexate-loaded nano lipid polymer system (MTX-NLPHS) that can transport methotrexate (MTX) in MCF-7 cell lines in a controlled manner through endocytosis via phosphatidylcholine. In this experiment, MTX is embedded with polylactic-co-glycolic acid (PLGA) in phosphatidylcholine, which acts as a liposomal framework for regulated drug delivery. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and dynamic light scattering (DLS) were utilized to characterize the developed nanohybrid system. The particle size and encapsulation efficiency of the MTX-NLPHS were found to be 198 ± 8.44 nm and 86.48 ± 0.31 %, respectively, which is suitable for biological applications. The polydispersity index (PDI) and zeta potential of the final system were found to be 0.134 ± 0.048 and -28 ± 3.50 mV, respectively. The lower value of PDI showed the homogenous nature of the particle size, whereas higher negative zeta potential prevented the system from agglomeration. An <i>in vitro</i> release kinetics was conducted to see the release pattern of the system, which took 250 h for 100% drug release This kind of system may carry the drug for a long time in the circulatory system and prevent the drug discharge. Other cell culture assays such as 3-(4, 5-dimethyl thiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) and reactive oxygen species (ROS) monitoring were used to see the effect of inducers on the cellular system. MTT assay showed cell toxicity of MTX-NLPHS reduced at the lower concentration of the MTX, however, toxicity increased at the higher concentration of the MTX as compared to free MTX. ROS monitoring c revealed more scavenging of ROS using MTX-NLPHS as compared to free MTX. Confocal microscopy suggested the MTX-NLPHS induced more nuclear elongation with cell shrinkage comparatively.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 2","pages":"167-175"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10842959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and <i>In vivo</i> Pharmacokinetic and Pharmacodynamic Evaluation of an Oral Innovative Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan Formulation for Enhanced Bioavailability.","authors":"Narendar Dudhipala,&nbsp;Swetha Ettireddy,&nbsp;Ahmed Adel Ali Youssef,&nbsp;Goverdhan Puchchakayala","doi":"10.7150/ntno.78102","DOIUrl":"https://doi.org/10.7150/ntno.78102","url":null,"abstract":"<p><p><b>Background:</b> Irbesartan (IR) is used in the treatment of hypertension, heart failure, and nephropathy in Type II diabetes. IR bioavailability is limited by poor solubility and presystemic metabolism. In our previous investigations, cyclodextrin (HPβCD) complexed solid lipid nanoparticles (SLNs) of IR were prepared, optimized, and characterized. The current study aimed to confirm the reproducibility of the previous methodology and to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) performance of the selected lead formulations in an experimental animal model. <b>Methods:</b> SLNs were prepared by hot homogenization followed by probe sonication with IR/HPβCD inclusion complex loaded into a solid lipid (Dynasan 112). SLNs were evaluated for physical characteristics, drug content, entrapment efficiency, <i>in vitro</i> release profile, and surface morphology. The pharmacokinetic and pharmacodynamic behavior of the SLNs were evaluated in Wistar rats. <b>Results:</b> Photon correlation spectroscopy, drug content, entrapment efficiency, and dissolution studies results were reproducible and consistent with our earlier investigation. PK studies showed 2.1-, 6.6-, and 9.9-fold improvement in the relative oral bioavailability of the drug from IR-HPβCD, IR-SLN, and IR-HPβCD-SLN formulations, respectively compared to IR suspension. However, IR-HPβCD-SLNs showed 1.5- and 4.7-fold improvement in the relative oral bioavailability of the drug compared to IR-SLN and IR-HPβCD formulations, respectively. PD studies in hypertensive Wistar rats showed a good control over systolic blood pressure for 48 h for SLN formulations compared to 2 h for IR suspension. However, the IR-HPβCD inclusion complex exhibited immediate antihypertensive activity (0.5 h) with a period of systolic blood pressure control similar to IR suspension. <b>Conclusions:</b> The current approach exhibited improved oral bioavailability along with improved and prolonged pharmacodynamic effect.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 1","pages":"117-127"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10691063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Perspective on Using Organic Molecules Composing Carbon Dots for Cancer Treatment.","authors":"Musbahu Adam Ahmad,&nbsp;Yu-Yu Aung,&nbsp;Alfa Akustia Widati,&nbsp;Satya Candra Wibawa Sakti,&nbsp;Sri Sumarsih,&nbsp;Irzaman Irzaman,&nbsp;Brian Yuliarto,&nbsp;Jia-Yaw Chang,&nbsp;Mochamad Zakki Fahmi","doi":"10.7150/ntno.80076","DOIUrl":"https://doi.org/10.7150/ntno.80076","url":null,"abstract":"<p><p>Fluorescent Carbon dots (CDs) derived from biologically active sources have shown enhanced activities compared to their precursors. With their prominent potentiality, these small-sized (<10nm) nanomaterials could be easily synthesized from organic sources either by bottom-up or green approach. Their sources could influence the functional groups present on the CDs surfaces. A crude source of organic molecules has been used to develop fluorescent CDs. In addition, pure organic molecules were also valuable in developing practical CDs. Physiologically responsive interaction of CDs with various cellular receptors is possible due to the robust functionalization on their surface. In this review, we studied various literatures from the past ten years that reported the potential application of carbon dots as alternatives in cancer chemotherapy. The selective cytotoxic nature of some of the CDs towards cancer cell lines suggests the role of surface functional groups towards selective interaction, which results in over-expressed proteins characteristic of cancer cell lines. It could be inferred that cheaply sourced CDs could selectively bind to overexpressed proteins in cancer cells with the ultimate effect of cell death induced by apoptosis. In most cases, CDs-induced apoptosis directly or indirectly follows the mitochondrial pathway. Therefore, these nanosized CDs could serve as alternatives to the current kinds of cancer treatments that are expensive and have numerous side effects.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 2","pages":"187-201"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10851678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal NMR Based Serum Metabolomics to Track the Potential Serum Biomarkers of Septic Shock.","authors":"Swarnima Pandey,&nbsp;Afzal Azim,&nbsp;Neeraj Sinha","doi":"10.7150/ntno.79394","DOIUrl":"https://doi.org/10.7150/ntno.79394","url":null,"abstract":"<p><p><b>Background:</b> Septic shock, with a prolonged hospital stay, has the highest mortality rate worldwide. There is a need for better management of the disease, which requires time-dependent analysis of alteration occurring in the disease condition and subsequent planning of treatment strategies to curb mortality. <b>Objective:</b> The study aims to identify early metabolic signatures associated with septic shock before treatment and post-treatment. It also entails the progression of patients towards recovery, which clinicians could use to analyze treatment efficacy. <b>Methods:</b> The study was performed on 157 serum samples of patients with septic shock. We performed metabolomic, univariate, and multivariate statistics to identify the significant metabolite signature of patients prior to treatment and during treatment by collecting serum samples on the day I, day III, and day V of treatment. <b>Results:</b> We identified metabotypes of patients before treatment and post-treatment. The study showed time-dependent metabolite alteration in ketone bodies, amino acids, choline, and NAG in patients undergoing treatment. <b>Conclusion:</b> This study illustrates the metabolite's journey in septic shock and during treatment, which may be of prospective assistance to clinicians to monitor therapeutics.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 2","pages":"142-151"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10842963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Engineering Extracellular Vesicles to Target Pancreatic Tissue <i>In Vivo</i>: Erratum.","authors":"Hiroaki Komuro,&nbsp;Yuki Kawai-Harada,&nbsp;Shakhlo Aminova,&nbsp;Nathaniel Pascual,&nbsp;Anshu Malik,&nbsp;Christopher H Contag,&nbsp;Masako Harada","doi":"10.7150/ntno.75006","DOIUrl":"https://doi.org/10.7150/ntno.75006","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.7150/ntno.54879.].</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 1","pages":"90"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10459917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Image-Guided Nanodelivery of Pt(IV) Prodrugs to GRP-Receptor Positive Tumors.","authors":"Francisco Silva,&nbsp;Carolina Mendes,&nbsp;Alice D'Onofrio,&nbsp;Maria Paula Cabral Campello,&nbsp;Fernanda Marques,&nbsp;Teresa Pinheiro,&nbsp;Kyle Gonçalves,&nbsp;Sérgio Figueiredo,&nbsp;Lurdes Gano,&nbsp;Mauro Ravera,&nbsp;Elisabetta Gabano,&nbsp;António Paulo","doi":"10.7150/ntno.78807","DOIUrl":"https://doi.org/10.7150/ntno.78807","url":null,"abstract":"<p><p>Over the last decades, gold nanoparticles (AuNPs) have proven to be remarkable tools for drug delivery and theranostic applications in cancer treatment. On the other hand, Pt(IV) prodrugs have been employed as an interesting alternative to the more common Pt(II) complexes, such as cisplatin, for cancer chemotherapy. Searching to design an image-guided nanocarrier to deliver selectively Pt(IV) prodrugs to tumors expressing the gastrin releasing peptide receptor (GRPR), we have synthesized small core AuNPs carrying a thiolated DOTA derivative, a GRPR-targeting bombesin analog (BBN[7-14]) and a Pt(IV) prodrug attached to the AuNPs without (<b>AuNP-BBN-Pt1</b>) or with a PEGylated linker (<b>AuNP-BBN-Pt2</b> and <b>AuNP-BBN-Pt3</b>). In the GRPR+ prostate cancer PC3 cell line, the cytotoxic activity of the designed <b>AuNP-BBN-Pt</b> nanoparticles is strongly influenced by the presence of the PEGylated linker. Thus, <b>AuNP-BBN-Pt1</b> displayed the lowest IC₅₀ value (9.3 ± 2.3 µM of Pt), which is comparable to that exhibited by cisplatin in the same cell line. In contrast, <b>AuNP-BBN-Pt1</b> showed an IC₅₀ value of 97 ± 18 µM of Pt in the non-tumoral RWPE-1 prostate cells with a much higher selective index (SI) towards PC3 cells (SI = 10) when compared with cisplatin (SI = 1.3). The AuNPs were also successfully labeled with ⁶⁷Ga and the resulting <b>⁶⁷Ga-AuNP-BBN-Pt</b> were used to assess their cellular uptake in PC3 cells, with <b>AuNP-BBN-Pt1</b> also displaying the highest cellular internalization. Finally, intratumoral administration of <b>⁶⁷Ga-AuNP-BBN-Pt1</b> in a PC3 tumor-bearing mice showed a prolonged retention of the nanoparticle compared to that of cisplatin, with optimal <i>in vivo</i> stability and 20% of the injected platinum remaining in the tumor after 72 h post-injection. Furthermore, microSPECT imaging studies confirmed the uptake and considerable retention of the ⁶⁷Ga-labeled AuNPs in the tumors. Overall, these results show the potential of these targeted AuNPs loaded with Pt(IV) prodrugs for prostate cancer theranostics.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 1","pages":"22-40"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10691066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-resolution synchrotron K-edge subtraction CT allows tracking and quantifying therapeutic cells and their scaffold in a rat model of focal cerebral injury and can serve as a reference for spectral photon counting CT.","authors":"Clément Tavakoli,&nbsp;Elisa Cuccione,&nbsp;Chloé Dumot,&nbsp;Joëlle Balegamire,&nbsp;Salim Aymeric Si-Mohamed,&nbsp;Johoon Kim,&nbsp;Claire Crola-da-Silva,&nbsp;Yves Chevalier,&nbsp;Loïc Boussel,&nbsp;Philippe Douek,&nbsp;David Cormode,&nbsp;Hélène Elleaume,&nbsp;Emmanuel Brun,&nbsp;Marlène Wiart","doi":"10.7150/ntno.79575","DOIUrl":"https://doi.org/10.7150/ntno.79575","url":null,"abstract":"<p><p><b>Background:</b> The objective of this study was to demonstrate that synchrotron K-edge subtraction tomography (SKES-CT) can simultaneously track therapeutic cells and their encapsulating carrier, <i>in vivo,</i> in a rat model of focal brain injury using a dual-contrast agent approach. The second objective was to determine if SKES-CT could be used as a reference method for spectral photon counting tomography (SPCCT). <b>Methods:</b> Phantoms containing different concentrations of gold and iodine nanoparticles (AuNPS/INPs) were imaged with SKES-CT and SPCCT to assess their performances. A pre-clinical study was performed in rats with focal cerebral injury which intracerebrally received AuNPs-labelled therapeutic cells encapsulated in a INPs-labelled scaffold. Animals were imaged <i>in vivo</i> with SKES-CT and back-to-back with SPCCT. <b>Results:</b> SKES-CT revealed to be reliable for quantification of gold and iodine, whether alone or mixed. In the preclinical model, SKES-CT showed that AuNPs remained at the site of cell injection, while INPs expanded within and/or along the lesion border, suggesting dissociation of both components in the first days post-administration. Compared to SKES-CT, SPCCT was able to correctly locate gold, but not completely located iodine. When SKES-CT was used as reference, SPCCT gold quantification appeared very accurate both <i>in vitro</i> and <i>in vivo</i>. Iodine quantification by SPCCT was also quite accurate, albeit less so than for gold. <b>Conclusion:</b> We here provide the proof-of-concept that SKES-CT is a novel method of choice for performing dual-contrast agent imaging in the context of brain regenerative therapy. SKES-CT may also serve as ground truth for emerging technologies such as multicolour clinical SPCCT.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 2","pages":"176-186"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10842960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gold Nanoparticles Conjugated with Dendrigraft Poly-L-lysine and Folate-Targeted Poly(ethylene glycol) for siRNA Delivery to Prostate cancer.","authors":"Georges Minassian,&nbsp;Esther Ghanem,&nbsp;Roland El Hage,&nbsp;Kamil Rahme","doi":"10.7150/ntno.79050","DOIUrl":"https://doi.org/10.7150/ntno.79050","url":null,"abstract":"<p><p>Dendrigraft Poly-L-Lysine (d-PLL) coated gold nanoparticles (AuNPs) were synthesized by reducing Tetrachloroauric acid with ascorbic acid in the presence of d-PLL. AuNPs-d-PLL formed a stable colloidal solution that absorbs light at a maximum wavelength (λ_max) centered at 570 nm as demonstrated by UV-visible (UV-Vis) spectroscopy. From Scanning Electron Microscopy (SEM) analysis, AuNPs-d-PLL were spherical in shape with a mean diameter of 128 ± 47 nm. Dynamic Light scattering (DLS) analysis of the colloidal solution exhibited one size distribution with a hydrodynamic diameter of about 131 nm (size distribution by intensity). Zeta potential (ξ) measurements revealed positively charged AuNPs-d-PLL with ξ about 32 mV, an indicator of high stability in an aqueous solution. The AuNPs-d-PLL was successfully modified with either thiolated poly (ethylene glycol) SH-PEG-OCH₃ (M_w 5400 g mol^-1) or folic acid-modified thiolated poly (ethylene glycol) SH-PEG-FA of similar molecular weight as demonstrated via DLS and Zeta potential measurements. Complexation of PEGylated AuNPs-d-PLL with siRNA was confirmed by DLS and gel electrophoresis. Finally, we analyzed the functionalization of our nanocomplexes with folic acid via targeted cellular uptake to prostate cancer cells using flow cytometry and LSM imaging. Our findings implicate the broader applicability of folate-PEGylated AuNPs in siRNA-based therapeutics against prostate cancer and perhaps other types of cancer.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 2","pages":"152-166"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10851677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized biosensors for point-of-care diagnostics: from bench to bedside applications.","authors":"Pranjal Chandra","doi":"10.7150/ntno.81485","DOIUrl":"https://doi.org/10.7150/ntno.81485","url":null,"abstract":"<p><p>The most significant feature of translational point-of-care technology \"Personalized biosensors\" is that it can be done quickly and by clinical staff who are not trained in clinical laboratory sciences. Rapid test results can quickly give a doctor or other medical worker answers that can help them decide what to do or how to treat a patient. This is helpful almost everywhere, from the emergency room to a patient getting care at home. When a doctor meets a patient for the first time, during a flare-up of a known problem or when a new symptom shows up in a patient who is already being treated, having faster access to test results gives the doctor answers when they are with the patient or are about to see the patient which indicate the importance of point-of-care technologies and their future scope.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 2","pages":"210-215"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10851679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin Nanofiber PCL/PLGA/Collagen Enhanced the Therapeutic Efficacy of Mesenchymal Stem Cells against Liver Fibrosis in Animal Model and Prevented its Recurrence.","authors":"Gehan Abd-Elfatah Tawfeek,&nbsp;Hend Ahmed Kasem,&nbsp;Sherif Elsayed Elshoala","doi":"10.7150/ntno.81019","DOIUrl":"https://doi.org/10.7150/ntno.81019","url":null,"abstract":"<p><p>The aim of this study is preconditioning of hBM-MSCs using curcumin modified nanomembrane to optimize therapy of hepatic fibrosis and preventing its recurrence. <b>Methods:</b> The nanomembrane was prepared by electrospinning technique and characterized using conventional method (cur^- nanoscaffold and cur⁺ nanoscaffold). Kinetic release of curcumin was also measured by spectrophotometry. MSCs were isolated from human bone marrow (hBM-MSCs) and cultured on the both nanoscaffolds. We evaluated the <i>in-vivo</i> effect of hBM-MSCs from both nanoscaffold cultures (cur^- nanoscaffold/hMSCs and cur⁺ nanoscaffold/MSCs) on liver fibrosis from its effective and preventive points and we assessed the mechanisms of these effects as <i>in vitro</i> studies as cell proliferation, its effect on hepatogenic differentiation, its effect on paracrine release of hBM-MSCs and <i>in-vivo</i> studying the effect on cell migration, survival, engraftment, fate of transplanted cells, modifying the fibrogenic and inflammatory microenvironments. <b>Results:</b> The results of animal model showed that single injection of preconditioning of hBM-MSCs using curcumin modified nanoscaffold ameliorate the fibrosis and prevent its recurrence until 24 weeks of therapy in contrast to improvement but not ameliorative effect of hBM-MSCs/ curcumin negative nanoscaffold which recurred progressively after 12 weeks of therapy. These effects of curcumin modified nanoscaffold were results from its highly efficacy on cell proliferation, <i>in-vitro</i> and <i>in-vivo</i> hepatogenic differentiation, increasing cell migration, engraftment and survival in the inflammatory microenvironment which was markedly improved by down regulation of inflammatory mediators and upregulation of anti-oxidant factors. <b>Conclusion:</b> hBM-MSCs cultured on the prepared curcumin nanomembrane in this study is promising in regenerative therapy for ameliorating the hepatic fibrosis and to prevent its recurrence.</p>","PeriodicalId":36934,"journal":{"name":"Nanotheranostics","volume":"7 3","pages":"299-315"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9386898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}